Abstract | OBJECTIVE: METHODS: RESULTS: The frequency of IFABP genotype was 0.47 for A/A, 0.37 for A/T, and 0.16 for T/T, and the allelic frequency was 0.65 for A and 0.35 for T. No significant different was found in lipid levels in every genotype before treatment (P > 0.05). After 4 weeks of treatment, the levels of TC, TG, LDL-C, and apoB significantly decreased (P < 00.01), and the levels of HDH-C and apoA I significantly increased (P < 0.01). The total therapeutic efficacy on A54A and A54T were 97% and 95%, respectively. In the patients with T54T genotype after treatment, no significant difference in lipids levels was found except TG (P < 0.05), and the total efficacy was only 38%. The total therapeutic efficacies of fenofibrate on A54A and A54T were higher than those of T54T, and there was significant different between A54A and T54T (P < 0.01). CONCLUSION: The polymorphism of human IFABP gene in hyperlipidemia is related with the therapeutic efficacy of fenofibrate, and the T54T IFABP genotype may have strong negative effect on such efficacy.
|
Authors | Xiao-tong Chang, Zhen-hui Wang, Xin Du, Ming-gang Dong, Li-juan Hou, Jie Liu, Jian Wang, Jian-guang Zhou |
Journal | Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
(Zhongguo Yi Xue Ke Xue Yuan Xue Bao)
Vol. 28
Issue 2
Pg. 230-3
(Apr 2006)
ISSN: 1000-503X [Print] China |
PMID | 16733910
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Apolipoproteins
- Fatty Acid-Binding Proteins
- Hypolipidemic Agents
- Lipids
- Fenofibrate
|
Topics |
- Aged
- Apolipoproteins
(blood)
- Fatty Acid-Binding Proteins
(genetics)
- Female
- Fenofibrate
(therapeutic use)
- Gene Frequency
- Genotype
- Humans
- Hyperlipidemias
(blood, drug therapy, genetics)
- Hypolipidemic Agents
(therapeutic use)
- Lipids
(blood)
- Male
- Middle Aged
- Polymorphism, Genetic
- Treatment Outcome
|